Routine annual meeting filing with no earnings or operational news. The equity plan approval enables future equity grants but does not trigger immediate dilution. Monitor for subsequent option grants or S-8 filings that would indicate actual share issuance.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 3 $17.00entry
- T+1 · 6mo ago −1.82%α −2.23% · $16.69
- T+5 · 5mo ago −1.06%α +2.76% · $16.82
- T+20 · 5mo ago +23.06%α +24.06% · $20.92
- T+60 · 3mo ago +352.88%α +350.38% · $76.99
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Forte Biosciences filed an 8-K reporting the results of its 2026 annual meeting, where stockholders approved the amended and restated 2021 Equity Incentive Plan (adding 1,850,000 new shares for a total reserve of 5,190,000 shares) and re-elected three Class III directors. The filing is a routine governance update with no material financial data or operational changes.
Key Facts
- Stockholders approved the Amended and Restated 2021 Equity Incentive Plan with 11,911,879 votes for, 3,997,050 against, and 351,042 abstentions.
- The plan reserves 5,190,000 shares total, including 1,850,000 newly requested shares.
- Three Class III directors (Steven Kornfeld, Scott Brun, Paul A. Wagner) were re-elected.
- KPMG LLP was ratified as independent auditor for FY2026 with 17,722,893 votes for.
- Advisory vote on executive compensation passed with 12,143,153 votes for.
- No officer departures, no financial results, and no guidance were reported.
Financial Impact
No financial figures reported; the equity plan adds 1,850,000 new shares to the reserve, representing potential future dilution of approximately 9% of the 20,478,817 shares outstanding.
Risk Factors
- Potential future dilution from equity awards under the approved plan.
- No cross-filing context provided; no other corporate events to assess.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-253436 |
| Document: d110060d8k.htm | 0001193125-26-253436 |
| Document: 0001193125-26-253436-index-headers.html | 0001193125-26-253436 |
| Document: 0001193125-26-253436-index.html | 0001193125-26-253436 |
| Document: 0001193125-26-253436.txt | 0001193125-26-253436 |
Track record
15 reports on FBRX
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +39.79% at T+60 after the Apr 8, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
- Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
- Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
- Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
- Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
- Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
- Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
- Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
- Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers